These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 25220191)

  • 21. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
    Nauck M; Wilhelm B
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.
    Wysham CH; Lin J; Kuritzky L
    Postgrad Med; 2017 May; 129(4):436-445. PubMed ID: 28294702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials.
    Raccah D; Lin J; Wang E; Germé M; Perfetti R; Bonadonna RC; de Pablos-Velasco P; Roussel R; Rosenstock J
    J Diabetes Complications; 2014; 28(1):40-4. PubMed ID: 24246441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
    Bolli GB; Owens DR
    Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
    Fournier M; Germe M; Theobald K; Scholz GH; Lehmacher W
    Ger Med Sci; 2014; 12():Doc14. PubMed ID: 25332702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR; Traylor L; Mullins P; Landgraf W
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
    Trautmann ME; Vora J
    Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
    Abreu M; Tumyan A; Elhassan A; Peicher K; Papacostea O; Dimachkie P; Siddiqui MS; Pop LM; Gunasekaran U; Meneghini LF; Adams-Huet B; Li X; Lingvay I
    Diabetes Obes Metab; 2019 Sep; 21(9):2133-2141. PubMed ID: 31144435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
    Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
    Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
    Davies ML; Pham DQ; Drab SR
    Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
    Xu J; Yao D; Xia J
    J Clin Pharm Ther; 2021 Oct; 46(5):1245-1253. PubMed ID: 33675117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
    Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
    Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.